Ultragenyx Pharma Announces Resignation of Lars Ekman
On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharma (RARE) of his decision to retire from the Board of Directors of the Company (the “Board”), effective immediately after...
Neutral
or
Ultragenyx News & Analysis
-
-
Ultragenyx Pharma Appoints Eric Crombez as Chief Medical Officer
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding...
-
Ultragenyx earnings missed by $0.02, revenue topped estimates
Investing.com - Ultragenyx (NASDAQ: RARE) reported fourth quarter EPS of $-2.16, $0.02 worse than the analyst estimate of $-2.14. Revenue for the quarter came in at $103.35M versus the...
-
Ultragenyx Pharma Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance
Ultragenyx Pharma (RARE) reported Q2 EPS of ($2.26), $0.51 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $89.3 million versus the consensus estimate of...
-
Ultragenyx Pharma Misses Q1 EPS by 43c
Ultragenyx Pharma (RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus estimate of...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
